Through its role as network coordinator and clinical research development organization, Q-CROC has been able to collect a wide range of relevant evidence pertaining to clinical research in oncology in Quebec. This real world evidence constitutes a valuable observational tool capable of monitoring the vitality of this sector with the aim of better promoting it. Our […]

    The Biotechnology Innovation Organization (BIO) has released the largest ever study of clinical development success rates, with a focus on the advantages of using biomarkers in clinical trials.     Some of the conclusions:  Clinical trial programs that used selection biomarkers saw an overall likelihood of approval (LOA) from Phase I of 25.9%, compared to […]

  AstraZeneca launches integrated genomics approach to transform drug discovery and development.   Read the press release: https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-launches-integrated-genomics-approach-to-transform-drug-discovery-and-development-22042016.html#!

  MONTREAL, April 11, 2016 /CNW Telbec/ – Esperas Pharma Inc. (“Esperas”) today announced the initiation of a project to develop a new oral anticancer agent called ESP-01, in partnership with Quebec Clinical Research Organization in Cancer (Q-CROC). Esperas will develop ESP-01 in the province of Québec for the next three and a half years, […]